A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 5, 2003, Pages 383-389

  Tassopoulos, N C ^a   Ketikoglou, I ^b   Tsantoulas, D ^c   Raptopoulou, M ^d   Hatzis, G ^e   Vafiadis, I ^e   Sidiropoulos, L ^f   Kanatakis, S ^g   Anagnostopoulos, G ^a   Sypsa, V ^h   Hatzakis, Angelos ^h  

^a Western Attica General Hospital   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e LAIKO GENERAL HOSPITAL   (Greece)

^f Loimodon Hospital   (Greece)

^g RED CROSS HOSPITAL   (Greece)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chronic hepatitis C; Daily interferon; Interferon ; Randomized clinical trial; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 10744227417     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00439.x     Document Type: Article

References (27)

1. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26: 71-77.
2. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
3. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
4. Poynard T. Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
5. Barbaro G, DiLorenzo G, Soldini M et al. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naïve patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. J Hepatol 2000; 33: 448-455.
6. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 1151-1155.
7. EASL International Consensus Conference on Hepatitis C. Paris. Consensus Statement, 26-28, February 1999. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961.
8. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
9. Ferenci P, Brunner H, Nachbaur K et al. The Austrian Hepatitis Study Group. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001; 34: 1006-1011.
10. Bjoro K, Bell H, Hellum KB et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226-232.
11. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50: 253-258.
12. Tabon M, Laudi C, Delmastro B et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35: 517-521.
13. Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 989-993.
14. Helbling B, Stamenic I, Viani F et al. The Investigators of the Swiss Association for the Study of the Liver. Interferon and amantadine in naïve chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002; 35: 447-454.
15. Lindsay KL, Trepo C, Heintges T et al. The Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
16. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
17. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
18. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
19. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-653.
20. Mangi A, Villani MR, Minerva N et al. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol 2001; 34: 441-446.
21. Berg T, Hoffmann RM, Teuber G et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000; 20: 427-436.
22. Pol S, Nalpas B, Bourliere M et al. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31: 1338-1344.
23. Mangia A, Santoro R, Piattelli M et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol 2002; 37: 109-116.
24. de Ledinghen V, Trimoulet P, Winnock M et al. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol 2002; 36: 672-680.
25. Abbas Z, Hamid S, Tabassum S. High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy. J Gastroenterol Hepatol 2002; 17: 577-581.
26. DiMarco V, Ferraro D, Almasio P et al. Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. J Viral Hepat 2002; 9(5): 354-359.
27. Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33: 419-423.